GCDH: Key Enzyme in Citric Acid Cycle and Potential Drug Target

Target Name: GCDH

NCBI ID: G2639

GCDH

GCDH: Key Enzyme in Citric Acid Cycle and Potential Drug Target

GCDH (Glutaryl-Coenzyme A dehydrogenase) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules. GCDH is responsible for the conversion of pyruvate, a key intermediate in the TCA cycle, to acetyl-CoA, which then enters the TCA cycle to begin the process of generating ATP.

GCDH is a protein that is expressed in most tissues throughout the body, including the heart, liver, and kidneys. It is also expressed in the blood and lymphatic system. GCDH is a proton transporter, which means that it uses ATP to pump protons (H+) out of the cell and into the cell's external environment. This process is essential for maintaining the proper pH balance within the cell.

GCDH is also involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to a variety of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. GCDH has been shown to generate ROS by converting pyruvate to acetyl-CoA in the TCA cycle.

GCDH is a potential drug target for a variety of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. For example, studies have shown that GCDH is highly expressed in the brains of individuals with Alzheimer's disease, and that inhibiting GCDH has been shown to protect against the development of this disease. In addition, GCDH has been shown to be highly expressed in the livers of individuals with cancer, and that inhibiting GCDH has been shown to inhibit the growth and spread of these tumors.

In addition to its potential as a drug target, GCDH is also a potential biomarker for a variety of diseases. For example, GCDH has been shown to be highly correlated with the level of brain-derived neurotrophic factor (BDNF), a protein that is involved in the repair and regeneration of damaged brain tissue. In addition, GCDH has been shown to be highly correlated with the level of fibroblast growth factor (FGF), a protein that is involved in the growth and proliferation of cells.

GCDH is also involved in the production of various signaling molecules, including the production of carbonyl-containing oxygen derivatives (CO2), which can contribute to the production of reactive oxygen species (ROS) that can damage cellular components. This process is important for the regulation of cellular homeostasis and the maintenance of cellular function.

In conclusion, GCDH is a protein that is expressed in various tissues throughout the body and is involved in the conversion of pyruvate to acetyl-CoA in the TCA cycle. It is also involved in the production of ROS and has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and in the livers of individuals with cancer. In addition, GCDH is a potential drug target and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of GCDH in cellular metabolism and the development of disease.

Protein Name: Glutaryl-CoA Dehydrogenase

Functions: Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. Isoform Short is inactive

The "GCDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets